The Influence of Inflammation on Anemia in CKD Patients
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Anemia is frequently observed in the course of chronic kidney disease (CKD) and it is associated with diminishing the quality of a patient’s life. It also enhances morbidity and mortality and hastens the CKD progression rate. Patients with CKD frequently suffer from a chronic inflammatory state which is related to a vast range of underlying factors. The results of studies have demonstrated that persistent inflammation may contribute to the variability in Hb levels and hyporesponsiveness to erythropoietin stimulating agents (ESA), which are frequently observed in CKD patients. The understanding of the impact of inflammatory cytokines on erythropoietin production and hepcidin synthesis will enable one to unravel the net of interactions of multiple factors involved in the pathogenesis of the anemia of chronic disease. It seems that anti-cytokine and anti-oxidative treatment strategies may be the future of pharmacological interventions aiming at the treatment of inflammation-associated hyporesponsiveness to ESA. The discovery of new therapeutic approaches towards the treatment of anemia in CKD patients has become highly awaited. The treatment of anemia with erythropoietin (EPO) was associated with great benefits for some patients but not all.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weiss, G., & Goodnough, L. T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041809 · Cited by 3,800
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762 · cited 1×
“However, three large randomized controlled trials (The Normal Hematocrit Study (NHCT) [90], The Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) trial [94], and The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) [18] demonstrated that establishing and reaching higher hemoglobin…”
BackgroundA trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Besarab, A., Bolton, W. K., Browne, J. K., Egrie, J. C., Nissenson, A. R., Okamoto, D. M., Schwab, S. J., & Goodkin, D. A. (1998) · New England Journal of Medicine · doi:10.1056/nejm199808273390903 · Cited by 1,930 · cited 3×
“According to recommendations, in all adult patients, ESAs should not be used to intentionally increase the Hb concentration above 13 g/dL (130 g/L) (1A), as it may increase the risk of stroke [18], hypertension [89], vascular access thrombosis (in case of hemodialysis patients) [90], and it can be associated with high…”
BackgroundPigeon, C., Ilyin, G., Courselaud, B., Leroyer, P., Turlin, B., Brissot, P., & Loréal, O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008923200 · Cited by 1,697 · cited 1×
“It has been showed to increase the synthesis of hepcidin which may be the link between inflammation and anemia [38,86].”
BackgroundHepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation
Ganz, T. (2003) · Blood · doi:10.1182/blood-2003-03-0672 · Cited by 1,544 · cited 2×
“It has been shown that during inflammation increased hepcidin levels limited iron release from enterocytes, hepatocytes, and macrophages thus decreasing its availability for bacteria [2,64].”
BackgroundGanz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Babitt, J. L., & Lin, H. Y. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011111078 · Cited by 1,041 · cited 4×
“ESA treatment enhances erythropoiesis which leads to the exhaustion of iron pool, resulting in a relative iron deficiency [8].”
BackgroundInfluentialInterleukin-6 induces hepcidin expression through STAT3
Wrighting, D. M., & Andrews, N. C. (2006) · Blood · doi:10.1182/blood-2006-06-027631 · Cited by 983 · cited 1×
“Wrighting and Andrews [65] demonstrated that interleukin-6 induced hepcidin expression through signal transducer and activator of transcription 3 (STAT3).”
BackgroundRoxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813599 · Cited by 582
The Molecular Mechanism of Hepcidin-mediated Ferroportin Down-Regulation
De Domenico, I., Ward, D. M., Langelier, C., Vaughn, M. B., Nemeth, E., Sundquist, W. I., Ganz, T., Musci, G., & Kaplan, J. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-01-0060 · Cited by 434
Gunnell, J., Yeun, J. Y., Depner, T. A., & Kaysen, G. A. (1999) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(99)70259-3 · Cited by 305
Iron in innate immunity: starve the invaders
Ganz, T. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.011 · Cited by 284 · cited 2×
“Consequently, the phosphorylation, internalization, ubiquitination, and degradation of ferroportin in the lysosomes is triggered [11,62].”
BackgroundSasu, B. J., Cooke, K. S., Arvedson, T. L., Plewa, C., Ellison, A. R., Sheng, J., Winters, A., Juan, T., Li, H., Begley, C. G., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245977 · Cited by 251
Song, S.-N. J., Tomosugi, N., Kawabata, H., Ishikawa, T., Nishikawa, T., & Yoshizaki, K. (2010) · Blood · doi:10.1182/blood-2010-03-271791 · Cited by 228
Ashby, D. R., Gale, D. P., Busbridge, M., Murphy, K. G., Duncan, N. D., Cairns, T. D., Taube, D. H., Bloom, S. R., Tam, F. W. K., Chapman, R., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.013136 · Cited by 191
Hepcidin antimicrobial peptide transgenic mice exhibit features of the anemia of inflammation
Roy, C. N., Mak, H. H., Akpan, I., Losyev, G., Zurakowski, D., & Andrews, N. C. (2007) · Blood · doi:10.1182/blood-2006-10-051755 · Cited by 178
The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes
Zughaier, S. M., Alvarez, J. A., Sloan, J. H., Konrad, R. J., & Tangpricha, V. (2014) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2014.01.003 · Cited by 174
Icardi, A., Paoletti, E., De Nicola, L., Mazzaferro, S., Russo, R., & Cozzolino, M. (2013) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft021 · Cited by 158
Intravenous iron therapy: how far have we come?
Cançado, R. D., & Muñoz, M. (2011) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20110123 · Cited by 94
Metadata
- Authors
- Gluba-Brzózka, A., Franczyk, B., Olszewski, R., & Rysz, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-01-22
- Volume
- 21
- Issue
- 3
- Pages
- 725
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3001343938
- Cited by
- 175
- References
- 20
- FWCI
- 10.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.